Abstract:
Primary and secondary arterial hypertension is one of the most widespread pathologies of the cardiovascular system with a predominant lesion of vessels of the elastic smooth muscle type, which is accompanied by thickening of the vascular wall, hypertrophy of the intima-media complex, impaired endothelial function, and the formation of wall atherosclerotic substrates. Very often today, the increase in blood pressure in patients is not an independent clinical form butis combined with other chronic diseases: coronary heart disease, chronic kidney diseases, disorders of the metabolic profile (diabetes, gout, diffuse atherosclerosis), or acts as a controlled risk factor. In the modern internal medicine clinic, this is called poly- or comorbidity. Accordingly, combined drugs are used for the pharmacotherapy of polymorbid diseases with arterial hypertension. It is pathogenetically justified, clinically effective, and safe, because the treatment lasts a lifetime with the use of minimal dosages of the components in the drug, once a day, which increases the compliance of pharmacotherapy. The above-mentioned determined the main goal of the work – to conduct a clinical and pharmaceutical analysis of combined drugs in comorbid pathology.
